Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
CD28 and CTLA-4 (CD152) play a pivotal role in the regulation of T cell activation. Upon ligation by CD80 (B7-1) or CD86 (B7-2), CD28 induces T cell proliferation, cytokine production, and effector functions, whereas CTLA-4 signaling inhibits expansion of activated T cells and induces tolerance. Therefore, we hypothesized that co-stimulatory molecules that preferentially bind CD28 or CTLA-4 would have dramatically altered biological properties. We describe directed molecular evolution of CD80 genes derived from human, orangutan, rhesus monkey, baboon, cat, cow, and rabbit by DNA shuffling and screening. In contrast to wild-type CD80, the evolved co-stimulatory molecules, termed CD28-binding protein (CD28BP) and CTLA-4-binding protein (CTLA-4BP), selectively bind to CD28 or CTLA-4, respectively. Furthermore, CD28BP has improved capacity to induce human T cell proliferation and interferon-gamma production compared with wild-type CD80. In contrast, CTLA-4BP inhibited human mixed leukocyte reaction (MLR) and enhanced interleukin 10 production in MLR, supporting a role for CTLA-4BP in inducing T cell anergy and tolerance. In addition, co-stimulation of purified human T cells was significantly suppressed when CTLA-4BP was cotransfected with either CD80 or CD28BP. The amino acid sequences of CD28BP and CTLA-4BP were 61 and 96% identical with that of human CD80 and provide insight into the residues that are critical in the ligand binding. These molecules provide a new approach to characterization of CD28 and CTLA-4 signals and to manipulation of the T cell response.
Lazetic
Sasha
S
Department of Vaccines, Maxygen, Inc., Redwood City, California 94063, USA.
Leong
Steven R
SR
Chang
Jean C-C
JC
Ong
Randal
R
Dawes
Glenn
G
Punnonen
Juha
J
D000069594:Abatacept; D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D018122:B7-1 Antigen / Q000235:genetics / Q000378:metabolism; D018106:CD28 Antigens / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D060908:CTLA-4 Antigen; D002352:Carrier Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D032621:DNA Shuffling; D018076:DNA, Complementary / Q000235:genetics / Q000378:metabolism; D019143:Evolution, Molecular; D005434:Flow Cytometry; D006801:Humans; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000378:metabolism / Q000528:radiation effects; D008024:Ligands; D008969:Molecular Sequence Data; D011485:Protein Binding; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011994:Recombinant Proteins; D016415:Sequence Alignment; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D018106:CD28 Antigens; C468140:CD28-binding protein, human; D060908:CTLA-4 Antigen; C468141:CTLA-4-binding protein, recombinant; C556706:CTLA4 protein, human; D002352:Carrier Proteins; D016207:Cytokines; D018076:DNA, Complementary; D018796:Immunoconjugates; D007141:Immunoglobulin Fc Fragments; D008024:Ligands; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins; D000069594:Abatacept